Efficacy and safety of voclosporin in patients with proteinuria > 2 g/g (UKKW 2024) - Jun 8, 2024 - Abstract #376; 195; Location: HARRIS; P2, P3 | "In a pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, the addition of voclosporin to mycophenolate mofetil (MMF) and low dose glucocorticoids resulted in earlier and greater reductions in proteinuria, regardless of baseline demographics or disease characteristics. Conclusion Consistent with results from the overall pooled study population, patients with UPCR ≥2 g/g treated with voclosporin achieved significantly higher renal response rates than patients treated with MMF and low dose glucocorticoids alone while renal function in both arms remained comparable. This is clinically relevant given the lack of safe and effective therapies for patients with high proteinuria."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Dr Emily Littlejohn1; Dr Salem Almaani2; Dr Vanessa Birardi3; Dr Ernie Yap3; Dr Christopher Collins4; Sadiq Amed5
|